Suggestions

Du même auteur

Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes

Archive ouverte | Ramin-Mangata, Stéphane | CCSD

International audience. Total word count (including tables and figure legends): 3927 Number of tables and figures : 4 2 ABSTRACT (Word count 250) Background and aims-PCSK9 is an endogenous inhibitor of LDL receptor ...

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab

Archive ouverte | Thédrez, Aurélie | CCSD

International audience. OBJECTIVE: Evolocumab, a PCSK9 (proprotein convertase subtilisin kexin type 9)-neutralizing antibody, lowers low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholestero...

Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function

Archive ouverte | Ramin-Mangata, Stéphane | CCSD

International audience. Background and aims: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest that PCSK9 deficiency...

Chargement des enrichissements...